Last reviewed · How we verify
Kanarb (FIMASARTAN)
Kanarb works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.
Kanarb (Fimasartan) is a small molecule drug that targets the Type-1 angiotensin II receptor. It is used to treat hypertensive disorder, a condition characterized by high blood pressure. The commercial status of Kanarb is unknown, but it is likely patented as it is not widely recognized. Key safety considerations include its half-life of 5.5 hours, although its bioavailability and off-patent status are unknown. As a relatively new drug, its long-term effects and interactions are still being studied.
At a glance
| Generic name | FIMASARTAN |
|---|---|
| Target | Type-1 angiotensin II receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Mechanism of action
Think of it like a traffic jam: angiotensin II is like a traffic cop that tells blood vessels to narrow and slow down. Kanarb is like a traffic cop that tells the traffic cop to stand down, allowing blood vessels to relax and blood to flow more easily. This helps lower blood pressure and reduce the risk of heart disease.
Approved indications
- Hypertensive disorder
Common side effects
Key clinical trials
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions (PHASE1)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
- A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia
- Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study
- A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy (PHASE3)
- A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia (PHASE3)
- Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |